Key result
Discovery NM 530c CZT SPECT demonstrates high diagnostic accuracy for CAD with ~80% pooled sensitivity.
Why the study?
Does Discovery NM 530c CZT SPECT provide accurate diagnosis of CAD compared to invasive coronary angiography and other noninvasive modalities in patients with known or suspected CAD?
Meta-Analysis (n=510)
Does Discovery NM 530c CZT SPECT provide accurate diagnosis of CAD compared to invasive coronary angiography and other noninvasive modalities in patients with known or suspected CAD?
Odds Ratio: 14.19 (95% CI 8.47–23.77)
Discovery NM 530c CZT SPECT demonstrates high diagnostic accuracy and reliability for CAD assessment, with performance comparable to standard invasive and noninvasive modalities.
Background: Coronary artery disease (CAD) is the leading cause of cardiovascular mortality (CVD), accounting for 1 in 5 CVD-related deaths. The advent of noninvasive imaging modalities has driven the use of myocardial perfusion imaging (MPI) to improve diagnostic accuracy and clinical outcomes. Objectives: Building on the role of myocardial perfusion imaging (MPI), this meta-analysis assesses the diagnostic accuracy of the Discovery NM 530c CZT SPECT for CAD compared with invasive coronary angiography (ICA ± FFR) and noninvasive modalities, including PET, MRI, and coronary CT angiography. Methodology: We systematically searched six databases, identifying 1,587 studies, with 9 meeting inclusion criteria (510 patients, ≥18 years, known/suspected CAD). NM 530c CZT-SPECT was compared with coronary angiography (±FFR), PET, MRI, or coronary CTA within 90 days. Diagnostic test accuracy was assessed using sensitivity, specificity, predictive values, AUC, and DOR, analyzed in R (Version 2024.12.0+467) using "mada" and related packages. Results: In bivariate analysis, NM 530c CZT-SPECT showed pooled sensitivity of 0.804 (95% CI: 0.751–0.848) and specificity of 0.793 (95% CI: 0.722–0.850) with low heterogeneity (29.8% and 26.2%, respectively). The diagnostic odds ratio (DOR) was 14.19 (95% CI: 8.47–23.77), confirming high diagnostic accuracy. On subgroup analysis, the comparator group had no significant impact on DOR (QM (df = 1) = 0.100, p = 0.752). Against ICA, sensitivity was 0.814 (95% CI: 0.726–0.878) and specificity 0.731 (95% CI: 0.638–0.807) with minimal heterogeneity (2.4%). AUC of 0.84 underscores its clinical reliability. Conclusion: NM 530c CZT-SPECT exhibits high diagnostic accuracy, with consistent sensitivity and modestly lower specificity than other invasive and noninvasive modalities. Its high AUC underscores its reliability for CAD assessment in clinical practice.
No takes yet. Share an insight, caveat, or question.
Arham et al. (2025) conducted a meta-analysis in Coronary artery disease (n=510). Discovery NM 530c CZT SPECT vs. Invasive coronary angiography (±FFR), PET, MRI, or coronary CTA was evaluated on Diagnostic accuracy (DOR 14.19, 95% CI 8.47-23.77). Discovery NM 530c CZT SPECT demonstrated high diagnostic accuracy for coronary artery disease, yielding a pooled sensitivity of 0.804, specificity of 0.793, and a diagnostic odds ratio of 14.19.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: